Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|23 CitationsHormonal & GHFemale-friendly

PT-141 Dosing Protocol: Bremelanotide Research Guide

Also known as: Bremelanotide, Vyleesi, MC4R Sexual Wellness Peptide

Dose Range
1.75 mgResearch range
0Typical research window: 1.75 mg2.5 mg

Studied in published research — not a medical recommendation. Primary protocol (Standard Dosing Protocol): 1.75 mg, As needed, minimum 45 minutes before sexual activity.

Protocol at a Glance
How Often
As needed

As needed, minimum 45 minutes before sexual activity

A Typical Run
Single dose, not more than once per 24 hours

FDA-approved dosing for female hypoactive sexual desire disorder

How It's Taken
Vial

Subcutaneous (abdomen or thigh)

Evidence
Established

Human clinical trials or FDA-approved formulation exists

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u10u20u30u40u50u
Low end: 1.75 mg70 units

All U-100: 100 units = 1 mL. 2 doses in the vial at the low end.

Track the doses you run

Save PT-141 (Bremelanotide) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

PT-141 (Bremelanotide) supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$24.50 net$49.00
10mg Lyophilized Vial
$2.45/mg$4.90/mg retail
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$74.00
20mg vial
$3.70/mg
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$40.00
10mg vial
$4.00/mg
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$42.00
10mg vial
$4.20/mg
Core Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$43.00
10mg vial
$4.30/mg
Biotech Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$45.00
10mg vial
$4.50/mg
Peptyes
Horizon Analytical UPLC-MS COA, lot DPS-3230947 (99.21%); COA names Privilege Bio Labs (Peptyes says: its manufacturer)
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDEPROTOCOLS takes 10% off at checkout
$45.00
10mg vial
$4.50/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$54.99
10mg vial
$5.50/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$80.00
10mg vial
$8.00/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$89.00
10mg vial
$8.90/mg
BioLongevity Labs
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$47.97
5mg vial
$9.59/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

FDA-Approved MedicationTier 1 — Human Phase 3 RCT / Approved
Pharmacological Class
Central Melanocortin Receptor Agonist (MC1R / MC3R / MC4R)
Administration Route
Under-the-skin injection (Subcutaneous (abdomen or thigh) / Subcutaneous)
2026 FDA & 503A Status
FDA-approved melanocortin agonist (Vyleesi) for HSDD; widely prescribed via 503A compounding pharmacies and telehealth longevity clinics.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 1 — Human Phase 3 RCT / Approved: Multi-center randomized controlled human clinical trials (Phase 3) and/or regulatory approval
What is a Melanocortin Agonist?

A compound that activates melanocortin receptors (MC1R-MC5R) in the body. These receptors control pigmentation, sexual arousal, appetite, and inflammation. PT-141 (Bremelanotide) activates MC4R for sexual function. Melanotan 2 activates MC1R for tanning. Both are synthetic analogs of alpha-MSH.

PT-141 (Bremelanotide) is the same active compound as Vyleesi (Palatin Technologies). FDA approved for: Hypoactive sexual desire disorder (premenopausal women).

Bottom Line Up Front

PT-141 (Bremelanotide) is an FDA-approved melanocortin agonist for hypoactive sexual desire disorder in premenopausal women. It works centrally in the brain to increase sexual desire, unlike Viagra which works on blood flow. Nausea is the most common side effect (40%).

Best evidence for

Sexual desire disorder in women, erectile dysfunction in men

Weakest evidence for

General libido enhancement in healthy individuals

Pharma equivalent

Vyleesi (Palatin Technologies)

Studies on file

23 (21 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. PT-141 (Bremelanotide) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

PT-141 is a synthetic melanocortin receptor agonist primarily used for treating sexual dysfunction in both men and women. Unlike PDE5 inhibitors (Viagra/Cialis), it works centrally in the brain to increase sexual desire and arousal through melanocortin pathways rather than vascular mechanisms.

Mechanisms of Action

  • Activates melanocortin receptors (MC1R, MC4R) in the hypothalamus
  • Increases dopamine release in the medial preoptic area
  • Stimulates sexual arousal pathways without affecting blood pressure
  • 100% bioavailable via subcutaneous route

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Standard Dosing Protocol
clinical trial
1.75 mgAs needed, minimum 45 minutes before sexual activitySingle dose, not more than once per 24 hoursSubcutaneous (abdomen or thigh)clinical trial
Male Erectile Dysfunction Protocol
reported protocol
4-6 mgAs needed, 2-4 hours before activitySingle doseSubcutaneousclinical trial
Baseline & Mid-Cycle Biomarker Bloodwork Panel

HPG Axis & Neuroendocrine Hormone Biomarker Panel (PT-141 (Bremelanotide))

Track hypothalamic-pituitary-gonadal (HPG) pulsatility, gonadotropins, and sex-steroid balance before and during neuroendocrine peptide protocols.

Draw fasted morning labs (before 9:00 AM) at Baseline (Day 0) and Week 6–8

Total & Free Testosterone (LC/MS-MS)

Day 0 + Wk 6–8

Why track at baseline: Establishes baseline Leydig/ovarian androgen synthesis prior to GnRH or Kisspeptin stimulation.

Week 6–8 check: Verify preservation or restoration of endogenous Free & Total Testosterone.

LH (Luteinizing Hormone) & FSH

Day 0 + Wk 6–8

Why track at baseline: Directly measures anterior pituitary gonadotrope responsiveness (critical for Kisspeptin-10 & Gonadorelin).

Week 6–8 check: Confirm pulsatile LH/FSH maintenance without pituitary GnRH receptor desensitization.

Sensitive Estradiol (E2, LC/MS) & SHBG

Day 0 + Wk 6–8

Why track at baseline: Evaluates aromatase conversion and sex-hormone binding capacity affecting bioavailable hormone ratios.

Week 6–8 check: Maintain balanced Estradiol-to-Testosterone ratio and stable SHBG.

Prolactin, CBC / Hematocrit & CMP

Day 0 + Wk 6–8

Why track at baseline: Rules out hyperprolactinemia (which suppresses GnRH/libido) and tracks systemic metabolic health.

Week 6–8 check: Confirm normal Prolactin (<15 ng/mL) and healthy blood viscosity/liver markers.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

21 Human2 Animal

We provide clinically relevant applications for Food and Drug Administration (FDA)-approved medications (flibanserin and bremelanotide) and investigational therapies (Lorexys and testosterone combinations). Detailed study outcomes, safety profiles, and clinical strategies guide clinicians in appropriate diagnosis, patient selection, expectation setting, side effect management, and patient education, improving treatment outcomes and patient satisfaction.

Limitations: No placebo control reported. Review article — no new primary data.

2025|Clinical obstetrics and gynecology
PubMed

Clinicians must discern important distinctions between flibanserin, bremelanotide, and other agents when managing premenopausal HSDD. Further research with the most suitable clinical endpoints and consideration of patient factors are crucial before widespread adoption of flibanserin and bremelanotide.

Limitations: No placebo control reported. Review article — no new primary data.

2025|The Annals of pharmacotherapy
PubMed

Several other continuous and categorical outcomes generated modest apparent benefits, though nearly all of these outcomes were likely derived post-hoc. Across RECONNECT trial data from two prior publications and the current study, bremelanotide's benefits are statistically modest and limited to outcomes for which scant evidence of validity among women with HSDD exists.

Limitations: No placebo control reported. Review article — no new primary data.

2024|Journal of sex research
PubMed

Although data from clinical trials demonstrated a significant change in validated questionnaires, the overall clinical benefit appears to be modest. However, these results should be interpreted in the light of the dramatic challenges in conducting well-designed clinical trials for female sexual dysfunction, due to the significant placebo effect of pharmacotherapy, and the frequent use of outcome measures that are likely to be highly susceptible to expectation biases, such as long periods of recall of sexual and emotional response.

Limitations: Review article — no new primary data.

2023|Expert opinion on pharmacotherapy
PubMed

These approvals have also renewed excitement in the development of therapeutics targeting the melanocortin system. Here, we review the anatomy and function of the melanocortin system, discuss progress and challenges in developing melanocortin receptor-based therapeutics, and outline potential metabolic and behavioural disorders that could be addressed using pharmacological agents targeting these receptors.

Limitations: No placebo control reported. Review article — no new primary data.

2023|Nature reviews. Endocrinology
PubMed

Because bremelanotide is a cyclic peptide molecule with a molecular weight of 1025, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, bremelanotide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Limitations: No placebo control reported. Review article — no new primary data.

2022|The Urologic clinics of North America
PubMed

Studies showed improvements in desire, arousal, and orgasm scores when 1.75 mg of bremelanotide was administered before sexual activity compared to a placebo. Bremelanotide is a promising way to treat HSDD.

Limitations: Animal study only — human translation uncertain. Review article — no new primary data.

2022|Neurology international
PubMed

Animal studies suggest that bremelanotide may affect female sexual desire by activating presynaptic MC4Rs on neurons in the mPOA of the hypothalamus, leading to increased release of DA, an excitatory neurotransmitter that increases sexual desire. This review presents what is known about the mechanism of action of bremelanotide in the context of treating HSDD.

Limitations: No placebo control reported. Review article — no new primary data.

2022|CNS spectrums
PubMed

The clinical development program comprised 3500 subjects in 43 completed studies. In the phase 3 studies, subjects took bremelanotide for up to 18 months.

Limitations: Standard limitations apply. Check original paper for full discussion.

2022|Journal of women's health (2002)
PubMed

Include delineation of the process of care for pre- and postmenopausal women with HSDD; release of global position statement on testosterone therapy in women; updates on efficacy and safety of vaginal estrogen for genitourinary syndrome of menopause and bremelanotide for HSDD; removal of flibanserin alcohol REMS; and development of new technology to enhance bioavailability and brain delivery of treatments. The DSM-5 revision combining HSDD and FSAD into one diagnostic category is a less accurate characterization of these separate disorders and may hinder access to demonstrated effective treatments for the women with these conditions.

Limitations: No placebo control reported. Review article — no new primary data.

2022|Current psychiatry reports
PubMed

The last decade has seen an increase in the number and type of pharmacologic treatment options for dysfunction primarily associated with menopause and hypoactive sexual desire disorder. Recent publications and systematic reviews have strengthened the safety data of existing FDA-approved medications as well as off-label therapies.

Limitations: No placebo control reported. Review article — no new primary data.

2022|Current opinion in obstetrics &amp; gynecology
PubMed

In Study A, 27 of 30 bremelanotide subjects (90.0%) completed the trial and exhibited a significantly greater reduction in body weight after 16&#x2009;days versus placebo [least squares mean difference (95% CI), -1.3 (-1.9 to -0.8) kg; p&#x2009;<&#x2009;.0001]. Mean caloric intake in bremelanotide subjects was decreased versus placebo, with a magnitude of reduction of approximately 400&#x2009;kcal/day throughout Study A (p&#x2009;<&#x2009;.01).

Limitations: Standard limitations apply. Check original paper for full discussion.

2022|Diabetes, obesity &amp; metabolism
PubMed

Among 1202 patients included in the integrated and subgroup analyses, bremelanotide achieved statistically significant improvements in measures of increased desire and decreased distress associated with low desire across all age, weight, and BMI subgroups, and all baseline bioavailable testosterone quartiles, with few exceptions. Bremelanotide was further associated with statistically significant increases in reported sexual desire (p&#x2009;<&#x2009;0.05) in patients not taking hormonal contraceptives, and with a numerical advantage in those taking hormonal contraceptives.

Limitations: Standard limitations apply. Check original paper for full discussion.

2022|Journal of women's health (2002)
PubMed

The 2 recently approved medications for HSDD, flibanserin and bremelanotide, are reviewed as well as off-label treatments. Overall, HSDD represents a common yet likely underrecognized disorder that midwives and other health care providers who care for women across the life span are in a unique position to address.

Limitations: No placebo control reported. Review article — no new primary data.

2021|Journal of midwifery &amp; women's health
PubMed

Bremelanotide, with even weaker efficacy, capitalised on the regulatory precedent set by the approval of flibanserin. Reconsideration of regulatory decisions to approve these drugs is in order, as well as a broader examination of how future regulatory decisions can better address conflicts of interest and clinically meaningful benefit.

Limitations: No placebo control reported. Review article — no new primary data.

2021|Drug and therapeutics bulletin
PubMed

Bremelanotide's modest benefits on incompletely reported post-hoc measures of questionable validity in combination with participants substantially preferring to take placebo suggest that the drug is generally not useful. Kingsberg et al.'s data reporting and measurement practices were incomplete and lacked transparency.

Limitations: Review article — no new primary data.

2021|Journal of sex research
PubMed

Because of the validity of a dilution QC that showed accurate quantification of 10-fold diluted plasma samples (accuracy 99.4 %, precision < 6 %), the assay is suitable for bremelanotide quantification in its effective concentration range up to 100,000&#x2009;pg/mL. The ultra-sensitive assay was applied to the quantification of bremelanotide plasma concentrations after oral administration to beagle dogs, which indicated minimal oral absorption.

Limitations: Animal study only — human translation uncertain.

2021|Journal of pharmaceutical and biomedical analysis
PubMed

Bremelanotide is a synthetic peptide analogue of the neuropeptide hormone alpha melanocyte-stimulating hormone (&#x3b1;-MSH) with high affinity for the melanocortin type 4 receptor (thought to be important for sexual function), giving it the potential to modulate brain pathways involved in sexual response. This article summarizes the milestones in the development of bremelanotide leading to this first regulatory approval.

Limitations: No placebo control reported. Review article — no new primary data.

2020|Drugs
PubMed

Bremelanotide is a subcutaneous injection that can be administered as needed approximately 45 minutes prior to sexual activity. Bremelanotide is safe and has limited drug-drug interactions, including no clinically significant interactions with ethanol.

Limitations: No placebo control reported. Review article — no new primary data.

2020|The Annals of pharmacotherapy
PubMed

Study 301 began on January 7, 2015, and concluded on July 26, 2016. Study 302 began on January 28, 2015, and concluded on August 4, 2016.

Limitations: Standard limitations apply. Check original paper for full discussion.

2020|Obstetrics and gynecology
PubMed

This review discusses investigations of melanocortin agonists for the treatment of sexual dysfunction with emphasis on proposed sites and mechanisms of action in the central nervous system that appear to be involved in melanocortinergic modulation of sexual function. Current research validates use of melanocortinergic agents for the treatment of both male and female sexual dysfunction.

Limitations: Preliminary/pilot study — needs larger trials. No placebo control reported. Review article — no new primary data.

2007|Current topics in medicinal chemistry
PubMed

More women reported moderate or high sexual desire following bremelanotide treatment vs. placebo (P = 0.0114), and a trend toward more positive responses regarding feelings of genital arousal occurred after bremelanotide compared with placebo (P = 0.0833).

Limitations: Preliminary/pilot study — needs larger trials.

2006|The journal of sexual medicine
PubMed

PT-141 Palatin.

Human Study

Bremelanotide is a parenterally administered melanocortin receptor agonist that is used to treat female hypoactive sexual desire disorder. Bremelanotide has been reported to cause mild serum enzyme elevations during therapy and has been implicated in rare instances of clinically apparent acute liver injury.

Limitations: No placebo control reported. Review article — no new primary data.

2004|Current opinion in investigational drugs (London, England : 2000)
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Do not combine with PDE5 inhibitors (Viagra, Cialis) - risk of severe hypotension
  • •Nausea occurs in ~40% of users, lasting 2+ hours
  • •Contraindicated in uncontrolled hypertension or cardiovascular disease
  • •May cause flushing and increased body temperature
  • •Not for use in pregnancy
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get PT-141 (Bremelanotide), baseline labs & clinician oversight.

Full PT-141 (Bremelanotide) $/mg comparison →
50% OFF AUTO-APPLIED$2.45/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy PT-141 (Bremelanotide): best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Ascension Peptides — $2.45/mg (10mg Lyophilized Vial, $24.50)
  2. 2. Pure Peptides — $3.70/mg (20mg vial, $74.00)
  3. 3. Polaris Peptides — $4.00/mg (10mg vial, $40.00)

Where is the cheapest place to buy PT-141 (Bremelanotide)?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $2.45/mg (10mg Lyophilized Vial, $24.50 after the 50% new-customer partner-link discount). We compared 11 US suppliers with live, checked prices.

How much does PT-141 (Bremelanotide) cost per mg?

Verified US domestic prices currently range from $2.45/mg to $9.59/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is PT-141 (Bremelanotide) approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.